Press Releases

Pierre Fabre

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel

Tabelecleucel

Pierre Fabre Pharmaceuticals Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics

Pierre Fabre

Pierre Fabre Laboratories begins next chapter, opening its new US office in Secaucus, NJ

Tabelecleucel

Updated results of Phase III ALLELE Study presented at ASH annual meeting confirm efficacy, safety, and durability of novel allogeneic cell therapy Tabelecleucel in relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD)

PFL-002 / VERT-002

Pierre Fabre Laboratories announce first patient dosed in Phase I/II clinical trial of PFL-002/VERT-002, an innovative targeted therapy intended to treat non-small cell lung cancer with MET alterations

Tabelecleucel

Pierre Fabre Laboratories announces the submission by Atara Biotherapeutics of Tabelecleucel Biologics License Application for treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease with U.S. FDA

Exarafenib

Kinnate Biopharma Inc. sells its investigational pan-RAF inhibitor, Exarafenib, to Pierre Fabre Laboratories

Tabelecleucel

Atara Biotherapeutics and Pierre Fabre Laboratories announce publication of Phase III ALLELE Tabelecleucel Data in The Lancet Oncology

Pierre Fabre

Foundation Medicine announces collaboration with Pierre Fabre Laboratories to develop companion diagnostics in non-small cell lung cancer

Tabelecleucel

Pierre Fabre Laboratories to accelerate their development in onco-hematology by acquiring the license for a breakthrough T-cell immunotherapy in North America

Pierre Fabre

Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology

PFL-002 / VERT-002

Pierre Fabre Laboratories acquires Vertical Bio and its innovative targeted therapy candidate for patients suffering from non-small cell lung cancer with MET alteration

ER004

Pierre Fabre and the EspeRare Foundation start the EDELIFE clinical trial of a prenatal treatment for a rare genetic disease, XLHED